Day 1 :
Wayne State University School of Medicine, USA
Time : 9:30 am
Dr. Vinod B. Shidham is a certified Anatomic and Clinical Pathologist and Cytopathologist by American Board of Pathology. His spectacular career started in Nagpur (Maharashtra State). After serving in academia in India up to the level of Professor of Pathology at Grant Medical College and JJ Group of Hospitals in Mumbai till 1985, he left for middle east and then to USA. Currently, he is Professor of Pathology at Wayne State University School of Medicine, Karmanos Cancer Center, & Detroit Medical Center, Detroit, MI in USA. He is Vice-chair- Anatomic Pathology and Director of Cytopathology, Cytotechnology School, Cytopathology fellowship training program, GI pathology fellowship, and Pathology Residency Training Program.
Dr. Shidham is a strong proponent of ‘Open access’ philosophy in academic publications. He is editor-in-chief of ‘CytoJournal” which is a peer-reviewed, PubMed indexed open access journal publishing high-quality papers in cytopathology. He is editor of upcoming monographs on ‘EUS-FNA of pancreas’ and ‘FNAB procedure’ as CytoJournal Monograph & Atlas Series on timely topics.
His areas of interest and expertise include cytopathology (fine needle aspiration biopsy- both technical and interpretation, serous cavity fluid cytopathology, pulmonary cytopathology, intraoperative cytopathology, emerging technologies in cytopathology, molecular cytopathology) and surgical pathology (soft tissue tumors, gastrointestinal pathology).
Department of Diagnostic and Clinical Health Sciences, SHRP, UMC
Keynote: Histopathological evaluation of fibrous tissue surrounding bioceramic delivery systems in sheep and rodent models
Time : 10:00 am
Dr. Benghuzzi is a Professor at the University of MS Medical Center. He is known nationally and internationally as a pioneer in Ceramic Drug Delivery Systems. He has over 250 PubMed indexed articles and over 700 abstracts detailing the release characteristics of various biologicals from the bioceramic carriers. He has trained more than 40 PhD students who are actively involved in academic careers. He has mentored students at all levels (from high school, undergrad, grad, post doc and faculty). He has served as a mentor for residents and faculty on more than 10 funded grants. He has been in research leadership roles in many organizations such President of the Academy of Surgical Research, Vice President of the Rocky Mountain Bioengineering Society, President of MAS, Academy’s Executive Director, and also organized and chaired several regional, national and international society programs. He has also served on numerous NIH special emphasis panels including R-25, K01, KO8, T-35, and the P-60 center grants. In addition, he has received numerous awards from various organizations during his career. A few of his awards included: (1) The Presidential Award from the RMBS, (2) Presidential Award from SEM International, (3) the Endocrine’s Society Outstanding Investigator Award, (4) MAS Contribution to Science Award, (5) The MAS Dudley Peeler Award, and (6) HEADWAE Award, (7) C. Hall Award, Outstanding Contribution to Biomedical Engineering (32nd SBEC), and (8) ISCM Excellence Award from the International Society for Ceramics in Medicine.
He was invited as a keynote/plenary to speak at state, national and international levels including recent invitations in France, Italy, Spain, Greece, China, Poland, Dubai and Canada. He is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) as well as an International Fellow of Biomaterials Science and Engineering (FBSE).
The major challenges faces vast majority of orthopedic and dental implants are: (i) biocompatibility, (ii) resorbability and (iii) maintenance of mechanical strength. Several studies conducted in our laboratories have documented the effectiveness of various ceramic drug delivery systems (CDDS) in regulating fertility in females as well as males. It was observed that the mode of sustained delivery of reproductive hormones from CDDS was governed and regulated by the development of capsular tissue surrounding the implantable CDDS. This investigation was specifically designed to correlate the thickness of fibrous capsule and the various histopathological components that are seen in the fibrous capsule surrounding ALCAP, HA, and TCP ceramics at the S/C and I/P implantation sites in small (rats) and large (sheep) animals. Male albino rats and castrated adult rams were utilized for these studies. All experimental animals were implanted either S/C or I/P with ALCAP, HA, and TCP ceramics delivery devises loaded with 40 mg testosterone. At 90 days post- implantation, the animals in all groups were euthanized and the fibrous tissue surrounding the ceramic devices and internal organs were harvested. After routine histological processing, sections of tissue were stained with hematoxylin and eosin as well as special stains and evaluated using light microscopy. Analysis of the data revealed the followings: 1) development of fibrous tissue around the implants did not show any significant difference in small or large animals, 2) capsular tissues retrieved from S/C site induced less fibrous tissue formation compared to I/P site in both models, 3) the presence of proinflammatory cells such as macrophages, neutrophils, fibroblasts, and vascularity, was found to be statistically different among the S/C implanted CDDS groups (p<0.01) compared to I/P implantation site, and 4) regardless of animal model, the ease of fibrous capsule thickness were ALCAP> HA>TCP, respectively. Results from these studies provided very important outcomes in which can be utilized to predict the longevity of the physical strength of CDDS and the duration of delivery profiles. The clinical impact of this investigation stems in the ability to develop biocompatible and effective delivery systems that ultimately will lead to fertility regulation.
Founder and CEO, HISTOWIZ, USA
Time : 10:30
Ke has over 10 years of experience in mouse histopathology and cancer research. She finished her PhD in Cancer Biology from Pier Paolo Pandolfi's lab at Harvard and led a team of investigators to publish papers in journals such as Nature and Blood. Prior to founding HistoWiz, she worked at a cancer diagnostics company (NASDAQ: CGIX) and did a postdoctoral fellowship with Douglas Hanahan at the Swiss Institute of Experimental Cancer Research.
HistoWiz is a biotechnology company that automates histology and has built an intelligent tissue platform for biomedical researchers in academia and pharmaceutical industry. Our mission is to fight cancer cooperatively instead of individually. Unlike core facilities and CROs, HistoWiz guarantees a 48-hour turnaround time from fixed tissue specimens to digital slides online. Histowiz shares the scanned images with researchers via a cloud system, allowing for unprecedented viewing, archival, collaboration, tagging, search and meta-analysis of histology data.
HistoWiz has the largest online preclinical pathology database in the world growing at 220% a year. PathologyMapTM employs a novel image-tagging technology to capture key information such as species, disease, organ, experimental treatment, genetic background and biomarker information. This online platform allows researchers to compare histology data and discover new insights from hundreds of academic institutions (e.g. MSKCC, Harvard, Johns Hopkins, CSHL, Cornell, Dana Farber, NIH, MD Anderson, Stanford, the Jackson Lab, HHMI and Cancer Research UK). It also enables the development of machine learning tools for cancer diagnosis, prognosis and personalized therapy. The three machine learning tools currently being developed at HistoWiz are automatic tumor identification, mitosis count, and image similarity search.
PathologyMapTM allows cancer researchers, clinicians, medical students, computer programmers and anyone interested in learning more about histopathology to access the latest discoveries in the cancer research community.
Northwestern University, United States
Keynote: High grade B-cell lymphomas in children: Focus on new entities created in the 2017 revision of the World Health Organization classification of tumors of hematopoietic and lymphoid tissues
Time : 11:00
Dr. Shunyou Gong is the director of Hematopathology and Hematopathology at the Ann & Robert H. Lurie Children’s Hospital of Chicago and an assistant professor at Northwestern University Feinberg School of Medicine. Dr. Gong’s clinical interests and areas of expertise include pediatric hematopoietic malignancies, inherited bone marrow failure syndromes, and bleeding or thrombotic disorders. As a first-author or corresponding author, he has published many landmark papers on prestigious journals including Cell, Blood, and American Journal of Surgical Pathology.
The 2017 revision of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (2017 WHO) has created several new provisional entities of high-grade B-cell lymphomas, including Burkitt-like lymphoma with 11q aberration, high grade B-cell lymphoma, not otherwise specified (NOS), and high grade B-cell lymphoma with C-MYC and BCL-2 and/or BCL-6 rearrangements (double hit or triple hit lymphomas). Little is known on the clinicopathologic features, diagnostic approaches, as wells as the prevalence of these new entities in pediatric patients. We collected pathologic and clinical data from the medical record on all pediatric high grade B-cell lymphoma (HGBL) cases diagnosed in the past 10 years at our institution (2007-2017). Nine cases that did not meet criteria for either BL or diffuse large B-cell lymphoma (DLBCL) underwent FISH for MYC, BCL-2, and BCL-6, as well as array comparative genomic hybridization (CGH). A total of 52 cases of HGBL were identified. These included 23 cases of classical Burkitt lymphoma (BL) as defined by classic morphology and MYC rearrangement, 20 cases of diffuse large B-cell lymphoma (DLBCL), and 9 other cases. Chromosome 11q aberrations were identified in 5 out of the 9 non-DLBCL, non-BL HGBL cases. The other 4 cases were classified as HGBL, not otherwise specified (NOS.) We did not identify any cases of HGBL with MYC and BCL-2 and/or BCL-6 rearrangements. Morphologically, all 5 cases of Burkitt-like lymphoma with 11q aberration showed typical pathological features as described in 2016 WHO. All 5 of these cases occurred in the head/neck region. Four of these cases were localized (stage II), with the remaining case also involving a few metabolically active but non-enlarged lymph nodes in the chest and abdomen (stage III). All 5 patients achieved complete remission with standard therapy for mature B-cell lymphoma. All patients were alive with no clinical evidence of disease at a median follow-up time of 34 months (range 12-95 months). Our results suggest that the majority of pediatric non-Burkitt, non-DLBCL cases of HGBCL carry 11q aberrations. In addition, patients with 11q aberrations appear to be more likely to present with lower stage disease, thus requiring less intensive therapy, and also tend to have primary disease in the head/neck. While HGBL-NOS does happen, double hit or triple hit lymphoma is almost never seen in Children. These findings further support the classification of Burkitt-like lymphoma with 11q aberration as a distinct pathologic and clinical entity.
UNESP: - Portal of the State University of São Paulo, Brazil
Time : 11:30
Noeme Sousa Rocha was graduated in Veterinary Medicine from State University of Maranhão (1989), completed Masters in Pathology from São Paulo State University (1994) and Ph.D. in Pathology from São Paulo State University (1998). She is currently an Associate Teacher of São Paulo State University, Brazil and she has experience in the area of veterinary medicine, with emphasis on animal pathology anatomy, acting on the following topics: veterinary, cytopathology, pathology, cancer and histopathology. She is also an Associate Member of the International Academy of Pathology.
Equine Melanoma – Anatomoclinical Expression and Biological Behavior: Immunohistochemistry techniques allow visualise for the visualization of specific markers relevant to the diagnosis and prognosis of neoplasms, since them they are characteristic of particular cellular events. In horses, variations in proliferation and adhesion markers expression were associated with the degree of melanoma malignancy. Although this tumor is not a recent entity, researches research has not accompanied the evolution of anatomoclinical diagnostic techniques. Due to it, we identified possible relationships between anatomoclinical expression and biological behavior, correlating them with the degree of tumor malignancy. For this, horses with the diagnosis of melanoma confirmed by cytopathological and histopathological exams were selected from the Archive of the Veterinary Pathology Department, without predilection for race, gender or age. Cytopathological slides were analyzed for the presence of atypical melanocytes, while those stained with HE were evaluated according to micrometric criteria of "Breslow". Furthermore, we analyzed the presence of lymphocytic infiltration, angiolymphatic invasion, necrosis and mitosis. Avidin-Biotin-Peroxidase technique was used for immunolabeling reactions that identify S-100, Ki-67, E-cadherin and CD44. Thus, cell receptors of the proliferative phase, loss of adhesion, migration and evasion were observed. Density of the immunolabellated immunolabeled cells of each antibody were determined by five fields of greatest magnification under optical microscope. The results were submitted to statistical analyzes analysis. We intend contribute to a better understanding of the biological behavior of this tumor, in order to demonstrate that a quickly carried out diagnosis containing several criteria of malignancy has significant importance in the patient’s prognosis.
Former President Russian Association of Clinical Cytologists Russia
Time : 12:00
Irina Shabalova has got her MD degree in Moscow Medical Institute, PhD in 1986 from Cancer Research Centre by P.N.Herzen, Sc.D. degree in 2002. Her practice as clinical cytologist begins from 1975. Positions: Unior Researcher, P.A. Herzens’Cancer Research Centre, Associate Professor, Central Institute of Postgraduated Education, Senior Researcher, N.N. Blokhin Cancer Research Centre, 2003 - Professor, Russian Medical Academy of Postgraduated Education. She has published more than 140 papers, 9 books. An editorial board member of the journals “Clinical Laboratory Diagnostics”, “Laboratory” (Russia), editorial Board member of “Acta Cytologica” (IAC), advisory Board member of “Cytopathology” (GB). MIAC, Past-president of the Russian Association of Clinical Cytologists.
Clinical cytology in Russia has been born in the body of Clinical laboratory diagnostics and hematology and starts to develop rapidly in early 60th. Moscow Cancer Research Centre by P.A. Herzen became a leader of diagnostics cytology: FNA and exfoliative material, rapid on site intraoperative, endoscopical and FNA evaluation, cervical screening etc. About 300 centralized cytological laboratories were founded in early 70th. The government system of quality control has been designed in 90th. Nowadays conventional and liquid-based cytology is used in clinical cytology for gynecological and non-gynecological samples as well as ancillary techniques such as immunocytochemistry, immunofenotyping, PCR, cytogenetics and other molecular studies. Automation was implemented to cervical screening in some laboratories. Russian Medical Academy of Continuous Professional Education plays an important role in scientific work, teaching and training: courses from 2 weeks to 3 month, monthly held ”Round Table”, computer classrooms, e-learning by lectures and scanned virtual slides etc.